Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Locally Advanced Breast Cancer|Hormone Receptor Positive Tumor
Interventions: DRUG: Abemaciclib|DRUG: Fulvestrant|DRUG: Aromatase Inhibitors
Sponsor: Duke University